Exact Sciences Corporation

As of December 31, 2025, Exact Sciences Corporation has 190.80M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 5.89, and the price-to-book ratio stands at -4.07.

As of December 31, 2025, Exact Sciences Corporation trades at an EV/EBITDA multiple of 920.08 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Exact Sciences Corporation trades at an EV/FCF ratio of 35.11, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2025, Exact Sciences Corporation maintains a current ratio of 2.43, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 105.07, indicating elevated leverage, while an interest coverage ratio of 0.95 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -3.53, reflecting losses generated across the asset base. Inventory turnover of 5.99 indicates how many times Exact Sciences Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on March 23, 2026, Exact Sciences Corporation's stock has gained approximately 129.96% over the past 52 weeks. The 50-day moving average sits at 103.09, while the 200-day moving average is 74.54.

Over the twelve months ended December 31, 2025, Exact Sciences Corporation posted a gross margin of 69.69, reflecting its pricing power and cost economics. The operating margin of -6.13 and net profit margin of -6.40 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield stands at 2.95, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.77, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Exact Sciences Corporation shareholders.

As of December 31, 2025, Exact Sciences Corporation has an Altman Z-Score of 2.19, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.